Cargando…

A drug comorbidity index to predict mortality in men with castration resistant prostate cancer

BACKGROUND: The Charlson Comorbidity Index is a poor predictor of mortality in men with castration resistant prostate cancer (CRPC). To improve this prediction, we created a comorbidity index based on filled prescriptions intended to be used in registry-based studies. MATERIALS AND METHODS: In a pop...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fallara, Giuseppe, Gedeborg, Rolf, Bill-Axelson, Anna, Garmo, Hans, Stattin, Pär
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318265/ https://www.ncbi.nlm.nih.gov/pubmed/34320037 http://dx.doi.org/10.1371/journal.pone.0255239

Ejemplares similares

Androgen deprivation therapy and excess mortality in men with prostate cancer during the initial phase of the COVID-19 pandemic
por: Gedeborg, Rolf, et al.
Publicado: (2021)

Prescription-based prediction of baseline mortality risk among older men
por: Gedeborg, Rolf, et al.
Publicado: (2020)

Population-based study on use of chemotherapy in men with castration resistant prostate cancer
por: Lissbrant, Ingela Franck, et al.
Publicado: (2013)

Modeling Disease Trajectories for Castration-resistant Prostate Cancer Using Nationwide Population-based Data
por: Ventimiglia, Eugenio, et al.
Publicado: (2022)

Long-term Outcomes Among Men Undergoing Active Surveillance for Prostate Cancer in Sweden
por: Ventimiglia, Eugenio, et al.
Publicado: (2022)

Use of 5α-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study
por: Robinson, David, et al.
Publicado: (2013)

Variation in Prostate-Specific Antigen Testing Rates and Prostate Cancer Treatments and Outcomes in a National 20-Year Cohort
por: Bergengren, Oskar, et al.
Publicado: (2021)

Population-based estimates of age and comorbidity specific life expectancy: a first application in Swedish males
por: Van Hemelrijck, Mieke, et al.
Publicado: (2022)

Survival Trend in Individuals With De Novo Metastatic Prostate Cancer After the Introduction of Doublet Therapy
por: Corsini, Christian, et al.
Publicado: (2023)

Susceptibility to SARS‐Cov‐2 infection and risk for severe COVID‐19 in patients with prostate cancer on androgen deprivation therapy
por: Gedeborg, Rolf, et al.
Publicado: (2022)

Mortality in men with castration‐resistant prostate cancer—A long‐term follow‐up of a population‐based real‐world cohort
por: Khoshkar, Yashar, et al.
Publicado: (2021)

Use of Antiepileptic Drugs and Risk of Prostate Cancer: A Nationwide Case-Control Study in Prostate Cancer Data Base Sweden
por: George, Gincy, et al.
Publicado: (2023)

Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden
por: Van Hemelrijck, Mieke, et al.
Publicado: (2010)

Mortality following Hip Fracture in Men with Prostate Cancer
por: Van Hemelrijck, Mieke, et al.
Publicado: (2013)

Observational study on time on treatment with abiraterone and enzalutamide
por: Fallara, Giuseppe, et al.
Publicado: (2020)

Risk of venous thromboembolism in men with prostate cancer compared with men in the general population: a nationwide population-based cohort study in Sweden
por: Balabanova, Yanina, et al.
Publicado: (2022)

Population-based study of long-term anticoagulation for treatment and secondary prophylaxis of venous thromboembolism in men with prostate cancer in Sweden
por: Balabanova, Yanina, et al.
Publicado: (2022)

Androgen deprivation therapy and excess mortality during the COVID-19 pandemic
por: Stattin, P., et al.
Publicado: (2021)

Temporal changes in cause‐specific death in men with localised prostate cancer treated with radical prostatectomy: a population‐based, nationwide study
por: Thomsen, Frederik B., et al.
Publicado: (2021)

Causes of death in men with localized prostate cancer: a nationwide, population‐based study
por: Van Hemelrijck, Mieke, et al.
Publicado: (2015)

Comparison of Relative Survival and Cause-Specific Survival in Men With Prostate Cancer According to Age and Risk Category: A Nationwide, Population-Based Study
por: Orrason, Andri Wilberg, et al.
Publicado: (2021)

How to model temporal changes in comorbidity for cancer patients using prospective cohort data
por: Lindhagen, Lars, et al.
Publicado: (2015)

5-α reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer
por: Robinson, David, et al.
Publicado: (2015)

Cohort Profile Update: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base—a refined prostate cancer trajectory
por: Van Hemelrijck, Mieke, et al.
Publicado: (2016)

Variations in the Uptake of Active Surveillance for Prostate Cancer and Its Impact on Outcomes
por: Ahlberg, Mats S., et al.
Publicado: (2023)

Association of Gonadotropin-Releasing Hormone Agonists for Prostate Cancer With Cardiovascular Disease Risk and Hypertension in Men With Diabetes
por: Lin, E., et al.
Publicado: (2022)

The Value of Real-World Data in Understanding Prostate Cancer Risk and Improving Clinical Care: Examples from Swedish Registries
por: Beckmann, Kerri, et al.
Publicado: (2021)

Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer
por: Crawley, Danielle, et al.
Publicado: (2016)

Changes in Characteristics of Men with Lethal Prostate Cancer During the Past 25 Years: Description of Population-based Deaths
por: Lycken, Magdalena, et al.
Publicado: (2022)

Association between atherogenic lipids and GnRH agonists for prostate cancer in men with T2DM: a nationwide, population-based cohort study in Sweden
por: Lin, E., et al.
Publicado: (2022)

Simulation model of disease incidence driven by diagnostic activity
por: Westerberg, Marcus, et al.
Publicado: (2020)

Exploring the association between use of gonadotropin releasing hormones agonists and prostate cancer diagnosis per se and diabetes control in men with type 2 diabetes mellitus: a nationwide, population-based cohort study
por: Lin, E., et al.
Publicado: (2021)

Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason Grade: Nationwide, population-based register study
por: Thomsen, Frederik B., et al.
Publicado: (2020)

Prospective study of Type 2 diabetes mellitus, anti‐diabetic drugs and risk of prostate cancer
por: Häggström, Christel, et al.
Publicado: (2016)

Determinants for choosing and adhering to active surveillance for localised prostate cancer: a nationwide population-based study
por: Bergengren, Oskar, et al.
Publicado: (2019)

Socioeconomic status and diagnosis, treatment, and mortality in men with prostate cancer. Nationwide population‐based study
por: Tomic, Katarina, et al.
Publicado: (2018)

Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer
por: Fallara, Giuseppe, et al.
Publicado: (2023)

A case-control study of lower urinary-tract infections, associated antibiotics and the risk of developing prostate cancer using PCBaSe 3.0
por: Russell, Beth, et al.
Publicado: (2018)

Satisfaction with Nurse-led Follow-up in Prostate Cancer Patients—A Nationwide Population-based Study
por: Bergengren, Oskar, et al.
Publicado: (2022)

Risk of Fractures and Falls during and after 5-α Reductase Inhibitor Use: A Nationwide Cohort Study
por: Robinson, David, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_lupddjifb0dol3a0mplk2lm6j2